tailieunhanh - Báo cáo y học: "β A randomized, controlled trial of interferon-β-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: β A randomized, controlled trial of interferon-β-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. | Available online http content 6 1 R73 Research article Open Access A randomized controlled trial of interferon-p-1a Avonex in patients with rheumatoid arthritis a pilot study iSrCTN03626626 Mark C Genovese1 Eliza F Chakravarty1 Eswar Krishnan1 and Larry W Moreland2 1 Division of Immunology and Rheumatology Stanford University Palo Alto CA USA 2Division of Rheumatology University of Alabama at Birmingham Birmingham AL USA Corresponding author Mark C Genovese e-mail Genovese@ Received 24 Sep 2003 Revisions requested 16 Oct 2003 Revisions received 17 Oct 2003 Accepted 23 Oct 2003 Published 7 Nov 2003 Arthritis Res Ther 2004 6 R73-R77 DOI ar1026 2004 Genovese et al. licensee BioMed Central Ltd Print ISSN 1478-6354 Online ISSN 1478-6362 . This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract The objective of this study was to evaluate the safety and possible efficacy of IFN-p-1a for the treatment of patients with rheumatoid arthritis RA . Twenty-two patients with active RA were enrolled in a phase II randomized double-blind placebo-controlled trial of 30 IFN-p-1a by weekly self-injection for 24 weeks. The primary outcome of the study was safety. Secondary outcomes included the proportion of patients achieving an American College of Rheumatology ACR 20 response at 24 weeks. There were no significant differences in Keywords clinical trials cytokines interferon-p rheumatoid arthritis therapy adverse events reported in the two groups. Fewer than 20 of patients in each arm of the study achieved an ACR 20 response at 24 weeks P . Sixty-nine percent of patients receiving IFN-p and 67 receiving placebo terminated the study early most of them secondary to a perceived lack of efficacy. Overall IFN-p-1a had a safety profile similar to that of placebo. There were no significant .